Join to access to all OVN content. Join for Free
It Can be Lonely in the Life of an MSL
Medical Science Liaison MSL mentorship KOL engagement professional development work-life balance

It Can be Lonely in the Life of an MSL


Share This Article


Summary

In this episode, Tom Caravela welcomes special guest Trish Gorecki to share her insights and experiences as a Medical Science Liaison (MSL). The conversation delves into overcoming challenges and frustrations in the MSL role, emphasizing the importance of mentorship and networking. Trish discusses coping strategies for isolation, handling setbacks, and improving Key Opinion Leader (KOL) engagement. The episode provides a comprehensive look at burnout, work-life balance, and effective time management, especially during travel. Trish highlights essential resources and tools for MSLs, stressing the significance of continuous personal and professional development. The episode concludes with final advice for both current and aspiring MSLs.

Key Points

  • Building and maintaining strong internal and external networks is crucial for overcoming the challenges and isolation often experienced by MSLs in the field.
  • Persistence and strategic relationship-building are key to gaining access to KOLs, especially in a competitive and evolving market landscape.
  • Taking personal responsibility for professional development through available resources, mentorship, and continuous learning can significantly enhance the effectiveness and satisfaction of MSLs.

Click for Source
Medical Science Liaison, MSL mentorship, KOL engagement, professional development, work-life balance

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
Over-Negotiation-How to Botch a Job Offer
Partner Avatar MSL Talk: Tom Caravela

Over-Negotiation-How to Botch a Job Offer

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Article
Clinical Educator Oncology Program Improves Adherence by 29%​
Partner Avatar iNIZIO

Clinical Educator Oncology Program Improves Adherence by 29%​

Explore OVN